A trial of Incyte's Pemazyre in patients with FGFR-altered brain cancer did not meet its primary endpoint but had encouraging secondary outcomes.

The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the ...